Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1223-1226

  Duman, Berna Bozkurt ^a   Şahin, Berksoy ^a   Ergin, Melek ^a   Guvenc, Birol ^a  

^a CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

CD20; Lymphoma; Resistance; Rituximab

Indexed keywords

CARBOPLATIN; CD19 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; AGED; ANTIGEN EXPRESSION; BONE MARROW BIOPSY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEMICOLECTOMY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MARGINAL ZONE LYMPHOMA; MELENA; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; REVIEW; STOMACH ULCER; VOMITING; WHOLE BODY CT; METABOLISM; PROGNOSIS; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84865803069     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9955-3     Document Type: Review

References (18)

1. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-68.
2. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czucman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non- Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135-43.
3. Kinoshita T, Nagai H, Murate T, Saito H. CD20 negative relapse in B-cell lymphoma after treatment with rituximab. J Clin Oncol. 1998;16:3916.
4. Grillo-Lopez AJ, Kunkel L. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin Cancer Res. 2000;6:317-8.
5. Schmitz K, Brugger W, Weis B, Kaiserling E, Kanz L. Clonal selection of CD20 negative non Hodgkin's lymphoma cells after treatment with anti CD20 antibody rituximab. Br J Haematol. 1999;106:571-2.
6. Foran JM, Norton AJ, Micallef IN, Taussιg DC, Amess JA, Rohatιner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimeric monoclonal chimeric anti CD20): a retrospective cohort analysis. Br J Haematol. 2001;114: 881-3.
7. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Gill D. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119: 412-6.
8. Alvaro-Naranjo T, Jaen-Martinez J, Guma-Pardro J, Bosch- Princep R, Salvado-Usach MT. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of literature. Ann Hematol. 2003; 82:585-8.
9. Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol. 2007;86:49-57.
10. Terui Y, Sakurai T, Mishima Y, et al. Identification of CD20 mutations in malignant lymphoma: can they be predictors of response to rituximab? Blood. 2005;106:288-9.
11. Sonoki T, Li Y, Miyanishi S, Nakamine H, et al. Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab. Int J Hematol. 2009;89(3):400-2.
12. Berinstein N, Grillo-Lopez A, White C, Bence Bruckler I, Maloney D, et al. Rituximab (ICEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
13. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-90.
14. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32.
15. Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin's lymphoma (B-NHL). Prog Proc Am Soc Clin Oncol. 2002;21:1286.
16. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684-8.
17. Amar-Maman D, Mounier N, Manson J, et al. Evaluation of efficacy and toxicity of rituximab plus aracytin-platinum(RDHAP) regimen in non Hodgkin lymphoma (NHL) relapsing patients. Blood. 2002;100:293a.
18. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traullé C, Salles G, Coiffier B. Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. Leuk Lymphoma. 2010; 51(3):399-405.